The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging.

The abundance and solubility of Abeta peptides are critical determinants of amyloidosis in Alzheimer's disease (AD). Hence, we compared levels of total soluble, insoluble, and total Abeta1-40 and Abeta1-42 in AD brains with those in age-matched normal and pathologic aging brains using a sandwich enzyme-linked immunosorbent assay (ELISA). Since the measurement of Abeta1-40 and Abeta1-42 depends critically on the specificity of the monoclonal antibodies used in the sandwich ELISA, we first demonstrated that each assay is specific for Abeta1-40 or Abeta1-42 and the levels of these peptides are not affected by the amyloid precursor protein in the brain extracts. Thus, this sandwich ELISA enabled us to show that the average levels of total cortical soluble and insoluble Abeta1-40 and Abeta1-42 were highest in AD, lowest in normal aging, and intermediate in pathologic aging. Remarkably, the average levels of insoluble Abeta1-40 were increased 20-fold while the average levels of insoluble Abeta1-42 were increased only 2-fold in the AD brains compared to pathologic aging brains. Further, the soluble pools of Abeta1-40 and Abeta1-42 were the largest fractions of total Abeta in the normal brain (i.e., 50 and 23%, respectively), but they were the smallest in the AD brain (i.e., 2.7 and 0.7%, respectively) and intermediate (i.e., 8 and 0.8%, respectively) in pathologic aging brains. Thus, our data suggest that pathologic aging is a transition state between normal aging and AD. More importantly, our findings imply that a progressive shift of brain Abeta1-40 and Abeta1-42 from soluble to insoluble pools and a profound increase in the levels of insoluble Abeta1-40 plays mechanistic roles in the onset and/or progression of AD.

• Publication year

  1999

• Venue

  Experimental Neurology

• Publication date

  1999-08-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1006/EXNR.1999.7085PMID 10415140
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular Pathology of Alzheimer’s Disease and Related Disorders

  1999cited by this paper
• Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques

  1999cited by this paper
• Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

  1998cited by this paper
• N‐terminal Heterogeneity of Parenchymal and Cerebrovascular Aβ Deposits

  1998cited by this paper
• Amyloid plaques in Guam amyotrophic lateral sclerosis/ parkinsonism-dementia complex contain species of Aβ similar to those found in the amyloid plaques of Alzheimer’s disease and pathological aging

  1998cited by this paper
• Detection of a Novel Intraneuronal Pool of Insoluble Amyloid β Protein that Accumulates with Time in Culture

  1998cited by this paper
• The presence of amyloid beta-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells.

  1998cited by this paper
• BIOSYNTHESIS OF APP AND Aβ: MULTIPLE PATHWAYS FOR THE GENERATION OF INTRACELLULAR Aβ

  1998cited by this paper
• Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan

  1998cited by this paper
• Amyloid beta-protein deposition in the leptomeninges and cerebral cortex.

  1997cited by this paper
• Amyloid β-Protein (Aβ) 1–40 But Not Aβ1–42 Contributes to the Experimental Formation of Alzheimer Disease Amyloid Fibrils in Rat Brain

  1997cited by this paper
• Unique Alzheimer's disease paired helical filament specific epitopes involve double phosphorylation at specific sites.

  1997cited by this paper
• Structural neurology: are seeds at the root of neuronal degeneration?

  1997cited by this paper
• The Neurofibrillary Pathology of Alzheimer's Disease

  1997cited by this paper
• The Pathogenesis of Senile Plaques

  1997cited by this paper
• Amyloid β‐protein deposition in the leptomeninges and cerebral cortex

  1997cited by this paper
• Amyloid beta-protein (Abeta) 1-40 but not Abeta1-42 contributes to the experimental formation of Alzheimer disease amyloid fibrils in rat brain.

  1997cited by this paper
• Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain.

  1996cited by this paper
• Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

  1996cited by this paper
• Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques.

  1996cited by this paper
• Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

  1996cited by this paper
• Alzheimer's disease : biology, diagnosis, and therapeutics

  1996cited by this paper
• β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease

  1996cited by this paper
• Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease.

  1996cited by this paper
• Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease.

  1996cited by this paper
• Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques.

  1996cited by this paper
• Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation.

  1996cited by this paper
• Amyloids and Are Generated Intracellularly in Cultured Human Neurons and Their Secretion Increases with Maturation (*)

  1996cited by this paper
• 530Amyloid protein (A) deposition in normal aging has the same characteristics as that in Alzheimer's disease: Predominance of A42(43) and association of A40 with cored plaques and microglial cells

  1996cited by this paper
• Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

  1995cited by this paper
• Maggot's hair and bug's eye: Role of cell interactions and intrinsic factors in cell fate specification

  1995cited by this paper
• Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques.

  1995cited by this paper
• Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in down Syndrome

  1995cited by this paper
• Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain

  1995cited by this paper
• Plaque-associated neuronal proteins: a recurrent motif in neuritic amyloid deposits throughout diverse cortical areas of the Alzheimer's disease brain.

  1994cited by this paper
• Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging.

  1994cited by this paper
• An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.

  1994cited by this paper
• Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)

  1994cited by this paper
• Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

  1994cited by this paper
• An extensive network of PHFτ‐rich dystrophic neurites permeates neocortex and nearly all neuritic and diffuse amyloid plaques in Alzheimer disease

  1994cited by this paper
• Human neurons derived from a teratocarcinoma cell line express solely the 695-amino acid amyloid precursor protein and produce intracellular beta-amyloid or A4 peptides.

  1993cited by this paper
• The Molecular and Genetic Basis of Neurological Disease

  1993cited by this paper
• Identification of normal and pathological aging in prospectively studied nondemented elderly humans.

  1992cited by this paper
• Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

  1992cited by this paper
• Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau.

  1992cited by this paper
• Defined neurofilament, tau, and beta-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques.

  1990cited by this paper
• Molecular biology of Alzheimer's disease.

  1989cited by this paper

• Maladaptive aging trajectory in late-onset Alzheimer's disease

  2026cites this paper
• Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer's disease.

  2026cites this paper
• Advances in PET imaging of protein aggregates associated with neurodegenerative disease

  2025cites this paper
• Aquaporin 4 modulation drives amyloid burden and cognitive abilities in an APPPS1 mouse model of Alzheimer's disease

  2025cites this paper
• Unlocking ferulic acid for neurological diseases and tailoring of nanoformulations to advance its brain delivery.

  2025cites this paper
• Particulate matter and co-occurring genetic risk induce oxidative stress and cardiac and brain Alzheimer’s pathology

  2025cites this paper
• Binding of Hg(I) and Hg(II) Ions to Amyloid‐Beta (Aβ) Peptide Variants Affect their Structure and Aggregation

  2025cites this paper
• Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review

  2025cites this paper
• Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double‐blind, placebo‐controlled phase 2 study

  2025cites this paper
• Interactions between daily sleep-wake rhythms, γ-secretase, and amyloid-β peptide pathology point to complex underlying relationships.

  2025cites this paper
• The MR1/MAIT cell axis enhances dystrophic neurite development in Alzheimer's disease

  2025cites this paper
• Proposed mechanisms of tau: relationships to traumatic brain injury, Alzheimer’s disease, and epilepsy

  2024cites this paper
• Induced expression of rabies glycoprotein in the dorsal hippocampus enhances hippocampal dependent memory in a rat model of Alzheimer’s disease

  2024cites this paper
• Alteration of gene expression and protein solubility of the PI 5-phosphatase SHIP2 are correlated with Alzheimer’s disease pathology progression

  2024cites this paper
• Re-Engineering Therapeutic Anti-Aβ Monoclonal Antibody to Target Amyloid Light Chain

  2024cites this paper
• Development of dietary small molecules as multi-targeting treatment strategies for Alzheimer's disease

  2024cites this paper
• Amyloid β accelerates age-related proteome-wide protein insolubility

  2024cites this paper
• Carotenoid Supplementation for Alleviating the Symptoms of Alzheimer’s Disease

  2024cites this paper
• Damage of the Phospholipid Bilayer by Aβ42 at Physiologically Relevant Peptide Concentrations.

  2024cites this paper
• Integrative Single-Plaque Analysis Reveals Signature Aβ and Lipid Profiles in the Alzheimer’s Brain

  2024cites this paper
• Effect of astaxanthin in type-2 diabetes -induced APPxhQC transgenic and NTG mice

  2024cites this paper
• Mechanistic insights into the role of amyloid-β in innate immunity

  2024cites this paper
• Cognitive impairments by formaldehyde exposure in Alzheimer's disease

  2024cites this paper
• Association of TMEM106B with Cortical APOE Gene Expression in Neurodegenerative Conditions

  2024cites this paper
• Dityrosine cross-linking and its potential roles in Alzheimer’s disease

  2023cites this paper
• Effects of Current Psychotropic Drugs on Inflammation and Immune System.

  2023cites this paper
• Rapid, scalable assay of amylin-β amyloid co-aggregation in brain tissue and blood

  2023cites this paper
• Protein Self-Assembly at the Liquid-Surface Interface. Surface-Mediated Aggregation Catalysis.

  2023cites this paper
• Extracellular Vesicle Treatment Alleviates Neurodevelopmental and Neurodegenerative Pathology in Cortical Spheroid Model of Down Syndrome

  2023cites this paper
• Upregulation of endocytic protein expression in the Alzheimer’s disease male human brain

  2023cites this paper
• A Function of Amyloid-β in Mediating Activity-Dependent Axon/Synapse Competition May Unify Its Roles in Brain Physiology and Pathology

  2023influential citation
• Genetic removal of synaptic Zn2+ impairs cognition, alters neurotrophic signaling and induces neuronal hyperactivity

  2023cites this paper
• TREM2 Alteration Increases AD Biomarkers and is Associated with Key Genes with 5xFAD Mice Model Analysis on MODEL-AD Database

  2023cites this paper
• Apicidin attenuates memory deficits by reducing the Aβ load in APP/PS1 mice

  2023cites this paper
• Amyloid β accelerates age-related proteome-wide protein insolubility.

  2023cites this paper
• Amyloid cascade hypothesis for Alzheimer’s disease. Does it work under physiological conditions?

  2023cites this paper
• Effect of a Standardized Extract of Asparagus officinalis Stem (ETAS®50) on Cognitive Function, Psychological Symptoms, and Behavior in Patients with Dementia: A Randomized Crossover Trial

  2023cites this paper
• Sepsis exacerbates Alzheimer’s disease pathophysiology, modulates the gut microbiome, increases neuroinflammation and amyloid burden

  2023cites this paper
• Amyloid- β Oligomers: Multiple Moving Targets

  2022cites this paper
• Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease

  2022cites this paper
• Importance of CSF-based Aβ clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathways

  2022cites this paper
• Artesunate restores mitochondrial fusion‐fission dynamics and alleviates neuronal injury in Alzheimer's disease models

  2022cites this paper
• Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer’s disease brain extracts

  2022cites this paper
• Elevated amyloid beta disrupts the nanoscale organization and function of synaptic vesicle pools in hippocampal neurons

  2022cites this paper
• Mitochondrial abnormalities in neurological disorders

  2021cites this paper
• IntelliCage Automated Behavioral Phenotyping Reveals Behavior Deficits in the 3xTg-AD Mouse Model of Alzheimer’s Disease Associated With Brain Weight

  2021cites this paper
• Refining the amyloid β peptide and oligomer fingerprint ambiguities in Alzheimer’s disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma

  2021cites this paper
• Neuroprotective Effects of Asparagus officinalis Stem Extract in Transgenic Mice Overexpressing Amyloid Precursor Protein

  2021cites this paper
• Generation of a humanized Aβ expressing mouse demonstrating aspects of Alzheimer’s disease-like pathology

  2021cites this paper
• Chronic PPARγ Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves Cognition

  2021cites this paper
• MUTYH Actively Contributes to Microglial Activation and Impaired Neurogenesis in the Pathogenesis of Alzheimer's Disease

  2021cites this paper
• Development of grape polyphenols as multi-targeting strategies for Alzheimer's disease.

  2021cites this paper
• Hippocampal Somatostatin Interneurons, Long-Term Synaptic Plasticity and Memory

  2021cites this paper
• Characterization of Homogeneous and Heterogeneous Amyloid-β42 Oligomer Preparations with Biochemical Methods and Infrared Spectroscopy Reveals a Correlation between Infrared Spectrum and Oligomer Size

  2021cites this paper
• Neuroinflammation in Alzheimer's disease and beneficial action of luteolin

  2021cites this paper
• Plaque-Associated Oligomeric Amyloid-Beta Drives Early Synaptotoxicity in APP/PS1 Mice Hippocampus: Ultrastructural Pathology Analysis

  2021cites this paper
• Alzheimer’s Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment

  2021cites this paper
• Mural Cells: Potential Therapeutic Targets to Bridge Cardiovascular Disease and Neurodegeneration

  2021cites this paper
• Symptomatic vs. Disease-Modifying Therapies

  2020cites this paper
• Nrf2 Suppresses Oxidative Stress and Inflammation in App Knock-In Alzheimer’s Disease Model Mice

  2020cites this paper
• The Erythrocytic Hypothesis of Brain Energy Crisis in Sporadic Alzheimer Disease: Possible Consequences and Supporting Evidence

  2020cites this paper
• Disease “Redefinition”: A Tough Pill to Swallow

  2020cites this paper
• Epilogue

  2020cites this paper
• ApoE mimetic improves pathology and memory in a model of Alzheimer's disease.

  2020cites this paper
• Disease Subtypes: The Promise and the Fallacy

  2020cites this paper
• The Scientific and Lay Narratives

  2020cites this paper
• The Hypothesis That Refuses to Die

  2020cites this paper
• Preface 2 – Enter Patient

  2020cites this paper
• Index

  2020cites this paper
• Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation

  2020cites this paper
• Passive immunotherapies targeting Aβ and tau in Alzheimer's disease

  2020cites this paper
• Pieces of a Puzzle?

  2020cites this paper
• Challenges Viewed from Afar

  2020cites this paper
• Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer’s Disease

  2020cites this paper
• Our Living Dissonance

  2020cites this paper
• Protein Paradox

  2020cites this paper
• β-amyloid: the known unknowns.

  2020cites this paper
• Biomarkers: The Promise and the Fallacy

  2020cites this paper
• Overexpression of Protein Kinase Mζ in the Hippocampus Mitigates Alzheimer's Disease-Related Cognitive Deficit in Rats.

  2020cites this paper
• Brain Fables

  2020cites this paper
• Note Added at Press Time – Reviving LOF

  2020cites this paper
• The Shaky Six and the “Second Reality”

  2020cites this paper
• Amyloid-β42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer’s disease

  2020cites this paper
• Inhibition of Aquaporin 4 Decreases Amyloid Aβ40 Drainage Around Cerebral Vessels

  2020cites this paper
• References

  2020cites this paper
• Predictions for the 2020s and Beyond

  2020cites this paper
• A microfiber scaffold-based 3D in vitro human neuronal culture model of Alzheimer's disease.

  2020cites this paper
• The Moonshot: Population-Based Studies of Aging

  2020cites this paper
• Lessons from Oncology

  2020cites this paper
• Preface 1 – The Question

  2020cites this paper
• The Fault in Our Models

  2020cites this paper
• Voluntary Wheel Running Reduces Amyloid-β42 and Rescues Behavior in Aged Tg2576 Mouse Model of Alzheimer’s Disease

  2019cites this paper
• A Pilot Study Comparing Effects of Bifrontal Versus Bitemporal Transcranial Direct Current Stimulation in Mild Cognitive Impairment and Mild Alzheimer Disease

  2019cites this paper
• Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia

  2019cites this paper
• Dietary supplementation of a high-temperature-processed green tea extract attenuates cognitive impairment in PS2 and Tg2576 mice

  2019cites this paper
• Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology

  2019cites this paper
• Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer’s disease patient brain samples

  2019cites this paper
• Differential activation of the mTOR/autophagy pathway predicts cognitive performance in APP/PS1 mice.

  2019cites this paper
• In Vivo Assessment of Retinal Biomarkers by Hyperspectral Imaging: Early Detection of Alzheimer's Disease.

  2019cites this paper
• In vivo localization of human acetylcholinesterase-derived species in a β-sheet conformation at the core of senile plaques in Alzheimer's disease

  2019cites this paper